Nexalin Technology News Today

HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device

The FDA has agreed on the design for Nexalin's planned clinical studies of the Gen-3 HALO Clarity, targeting insomnia and anxiety.

HOUSTON, TX, May 22, 2024 -- Nexalin Technology, Inc. is pleased to announce its new division, Nexalin America, has been selected to join the National Traumatic Brain Injury Registry Coalition ....

HOUSTON, TEXAS, April 25, 2024 -- Nexalin Technology, Inc. announced that the Company received notice from The Nasdaq Stock Market on April 23, 2024, notifying the Company that it has regained...

Nexalin Technology completed the first full production test run of its Gen-3 HALO Clarity insomnia neurostimulator.

The new Gen-3 HALO™ Clarity 15 milliamp HOUSTON, TX, April 09, 2024 -- Nexalin Technology, Inc. today announced it has completed the first full production test run and successfully...

The new Gen-3 HALO™ Clarity 15 milliamp (mA) HOUSTON, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or...

The USPTO has awarded Nexalin Technology Inc a new patent relating to its method of use, which covers key aspects of the technology that enables patients to receive treatment from the privacy of their homes.

Previously served as Acting General Counsel to the Department of Veterans AffairsHOUSTON, TEXAS, April 02, 2024 -- Nexalin Technology, Inc. , today announced the appointment of former Acting...